What does this research mean for the field?

In Angiotensin II-dependent hypertension, the augmentation of intrarenal and urinary angiotensinogen is mediated by AT1 receptors, as AT1 receptor blockade with olmesartan prevents these increases. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To determine whether the augmentation of intrarenal angiotensinogen levels and urinary angiotensinogen excretion in angiotensin II-dependent hypertension requires activation of AT1 receptors.

March 23, 2004HypertensionOpen Access

AT 1 Receptor Mediated Augmentation of Intrarenal Angiotensinogen in Angiotensin II-Dependent Hypertension

Q: What is the clinical evidence from this study?

Study design: Other. Population: Angiotensin II-Dependent Hypertension (n=33). Intervention: AT1 blocker (ARB), olmesartan vs. Sham surgery and Ang II infusion alone. Primary outcome: Kidney angiotensinogen levels (densitometric units).

View Full Paper

Ask AI

Bookmark

Key result

In Ang II-infused hypertensive rats, AT1 receptor blockade with olmesartan prevented the augmentation of kidney angiotensinogen (1.14 vs 1.69 densitometric units) and urinary angiotensinogen excretion.

Why the study?

Does AT1 receptor blockade with olmesartan prevent the augmentation of intrarenal angiotensinogen in Ang II-infused hypertensive rats?

Population

33 male Sprague-Dawley rats (200 to 220 g)

Comparison

Subcutaneous infusion of Ang II plus AT1 blocker… vs Sham surgery or subcutaneous infusion of Ang II…

Design

Preclinical

Follow-up

13 days

Authors

HKHiroyuki KoboriGeneral / Preventive / Lipids MPMinolfa C. Prieto‐CarrasqueroTulane University YOYuri OzawaTulane University

Discussion

Member takes

Implication

AT1 blockade may suppress intrarenal angiotensinogen in Ang II rat models; extends mechanistic data but leaves clinical translation open.

Key Points

To determine whether the augmentation of intrarenal angiotensinogen levels and urinary angiotensinogen excretion in angiotensin II-dependent hypertension requires activation of AT1 receptors.
Male Sprague-Dawley rats (200–220 g) were divided into 3 groups: sham surgery (n=10), subcutaneous infusion of Ang II at 80 ng/min (n=11), and Ang II infusion plus the AT1 receptor blocker olmesartan at 5 mg/d (n=12).
Systolic blood pressure was monitored through day 11, followed by 24-hour urine collection at day 12 and tissue/plasma harvesting at day 13 to measure Ang II and angiotensinogen expression.
Ang II infusion increased systolic blood pressure to 178±8 mm Hg versus 119±4 mm Hg in sham controls at day 11, whereas olmesartan co-treatment prevented hypertension (113±6 mm Hg at day 11).
Olmesartan limited kidney Ang II accumulation (288±28 fmol/g vs 606±147 fmol/g with Ang II alone and 65±17 fmol/g in sham) and prevented increases in kidney angiotensinogen (1.14±0.12 vs 1.69±0.21 densitometric units with Ang II alone and 1.00±0.17 in sham).
Ang II infusion produced a 4.7-fold increase in urinary angiotensinogen excretion (4.67±0.41 vs 1.00±0.21 densitometric units in sham), which was completely prevented by olmesartan treatment (0.96±0.23 densitometric units).

Structured PICO

Does AT1 receptor blockade with olmesartan prevent the augmentation of intrarenal angiotensinogen in Ang II-infused hypertensive rats?

Population

33 male Sprague-Dawley rats (200 to 220 g)

Intervention

Subcutaneous infusion of Ang II (80 ng/min) plus AT1 blocker (ARB) olmesartan (5 mg/d)

Comparator

Sham surgery (n=10) or subcutaneous infusion of Ang II alone (80 ng/min, n=11)

Outcome

Intrarenal angiotensinogen levels and urinary angiotensinogen excretionsurrogate

Main Result

Absolute Event Rate: 1.14% vs 1.69%

Cite This Study

Kobori et al. (2004) studied Angiotensin II-Dependent Hypertension (n=33). AT1 blocker (ARB), olmesartan vs. Sham surgery and Ang II infusion alone was evaluated on Kidney angiotensinogen levels (densitometric units). In Ang II-infused hypertensive rats, AT1 receptor blockade with olmesartan prevented the augmentation of kidney angiotensinogen (1.14 vs 1.69 densitometric units) and urinary angiotensinogen excretion.

synapsesocial.com/papers/6a16b4c64f6063e06b050cfc https://doi.org/10.1161/01.hyp.0000122875.91100.28

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

AT 1 Receptor Mediated Augmentation of Intrarenal Angiotensinogen in Angiotensin II-Dependent Hypertension

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Topics

AT 1 Receptor Mediated Augmentation of Intrarenal Angiotensinogen in Angiotensin II-Dependent Hypertension

Discussion

Member takes

Implication

Key Points

Structured PICO

Main Result

Cite This Study

Also Consider

Topics

Also Consider